JUL 26, 2017 6:00 AM PDT

Peptide Drugs Could Live a Longer (Half-) Life with This Chimera Ligand

Peptide and protein drugs like insulin are critical medications. Most of them cannot be taken orally because they will be digested in the intestine and broken down into amino acids and simple derivative compounds. When injected intravenously, peptides are subjected to fast excretion by the kidney and suffer from enzymatic degradation in the blood circulation, which results in short plasma half-life and a limited therapeutic time frame.

Modifications of peptides and proteins have proven to prolong their longevity in the blood. Shortening the amino acid chain and replacing L-analogue amino acids with D-amino acids can help to evade attack and cleavage by proteases in the blood. Alternatively, adding a fatty acid or short peptide moiety to the native polypeptide chain can allow the conjugated molecule to hitch a ride with serum proteins like albumin and stay in circulation longer.

Fatty acid ligands can extend the circulation half-life by helping the peptide piggy-back onto albumin. Take insulin detemir for example; it is a long-circulating human insulin analogue tagged with a myristic acid (a saturated fatty acid with a 14-carbon chain). It lasts for 5-7 hours in circulation. In comparison the tag-free insulin has only a 4-6 minute half-life. Most fatty acid-conjugated peptides show weak to moderate affinity for albumin. On the other hand, peptide-based ligands showed better affinity to albumin. However, they render the modified molecule hard to dissolve and distribute in blood, which significantly undermines the therapeutic effects of peptides.

The chimera ligand (green), which is conjugated with a model drug peptide (white), is seen bound to serum albumin (red) in the schematic drawing. Credit: C.Heinis/EPFL

To solve this conundrum, a team of Swiss researchers led by Dr. Christian Heinis at the École Polytechnique fédérale de Lausanne (EPFL) has now developed a chimera ligand, a fatty acid fused with a second short peptide, which combines the advantages of two moieties. In their design, the fatty acid alone can bind to albumin with a moderate affinity and with a low micromolar Kd (dissociation constant – smaller Kd means higher affinity), and the peptide moiety provides extra interaction with albumin to bring the Kd down to the nanomolar level. Through elaborate synthesis and screening of various candidates, they found one that binds to human albumin with high affinity (Kd=39 nM), is highly soluble, and can easily be tagged onto peptides via standard synthesis procedure. To verify the functionality of their design, the researchers tagged two bioactive peptides, PK128 and UK18, both of which are protease inhibitors that suffer from fast renal clearance. The half-life of the two test peptides was significantly prolonged over 25-fold, though one of them suffered a drop in its inhibitory activity.

The comparison of ligand designs. Credit: Ecole Polytechnique Federale de Lausanne

When speaking about the potential of the new ligand, the group leader expressed his hope for its application on a bigger scale. "We expect that the tag presented in our work will interest a larger research and business audience because it is applicable to virtually any peptide moiety, including small proteins. The ligand can be appended to any peptide during solid-phase peptide synthesis on standard synthesizers, making it easily accessible for academic and industry labs," said Dr. Heinis.

Source: Phys.org/Nature Communication

About the Author
  • Graduated with a bachelor degree in Pharmaceutical Science and a master degree in neuropharmacology, Daniel is a radiopharmaceutical and radiobiology expert based in Ottawa, Canada. With years of experience in biomedical R&D, Daniel is very into writing. He is constantly fascinated by what's happening in the world of science. He hopes to capture the public's interest and promote scientific literacy with his trending news articles. The recurring topics in his Chemistry & Physics trending news section include alternative energy, material science, theoretical physics, medical imaging, and green chemistry.
You May Also Like
JAN 28, 2020
Earth & The Environment
JAN 28, 2020
New way to generate electricity from heat
Have you ever heard of paramagnons? Perhaps not, but they’re worth another look – at least that’s what researchers from The Ohio State Un...
JAN 28, 2020
Chemistry & Physics
JAN 28, 2020
Radioactive Spill? Self-propelled Microbots to the Rescue
Scientists have been looking for an effective method to clean up radioactive elements in industrial wastewater and accidental spill, to support and boost t...
JAN 28, 2020
Chemistry & Physics
JAN 28, 2020
Pharmacist Who Debunked False Vit C Claim Honored by the Maddox Prize
"Sense about Science" is a UK-based NGO that promotes the public understanding of science. Every year the organization gives the John Maddox Priz...
JAN 28, 2020
Space & Astronomy
JAN 28, 2020
SpaceX's Starship Prototype Explodes During Pressure Test
SpaceX is best known for its Falcon-series of rockets that often resupply the International Space Station and ferry satellites into space to deploy an orbi...
JAN 28, 2020
Chemistry & Physics
JAN 28, 2020
Physics Breakthroughs in 2019
The Physics World magazine is an iconic publication in the scientific community. This month, its editorial team selected the top 10 Breakthroughs for...
JAN 28, 2020
Chemistry & Physics
JAN 28, 2020
Espresso, Scientifically
Everyone has their preferred way to make a cup of coffee, but for those who wish to become the master of espresso, now there's a highly scientific way...
Loading Comments...